Cutaneous Lupus Erythematosus Skin Punch Biopsy
Cutaneous Lupus Erythematosus Skin Punch Biopsy samples are collected from IRB-consented donors with clinically confirmed CLE, with lesional and non-lesional sites available. Suitable for interface dermatitis histopathology, direct immunofluorescence, type I interferon signature scoring, and spatial profiling of the cytotoxic T cell infiltrate at the dermal-epidermal junction. Stratification by CLE subtype, serology, and treatment status is available, with matched healthy controls.
Cutaneous Lupus Erythematosus Skin Punch Biopsy for Autoimmune Dermatology Research
Cutaneous Lupus Erythematosus Skin Punch Biopsy samples are collected from IRB-consented donors with a clinically confirmed diagnosis of cutaneous lupus erythematosus (CLE). Biopsies are taken by licensed clinicians under aseptic conditions and, where frozen material is requested, are frozen within 4 hours of collection. Lesional, non-lesional, and sun-protected sites can be requested. These specimens support histopathological, immunological, and molecular research into the autoimmune tissue injury that defines CLE.
Why Skin Tissue for Cutaneous Lupus Research
CLE is an autoimmune disease in which the target organ is the skin. The defining lesion is an interface dermatitis: a lymphocytic infiltrate at the dermal-epidermal junction with vacuolar change and apoptosis of basal keratinocytes. That pathology exists in the tissue and cannot be reconstructed from blood alone.
- Interface dermatitis, basement membrane thickening, follicular plugging, and dermal mucin are assessable only in intact tissue architecture, making punch biopsy the reference specimen for CLE histopathology.
- Direct immunofluorescence on lesional skin demonstrates immunoglobulin and complement deposition at the dermal-epidermal junction — the basis of the lupus band test.
- Lesional CLE skin shows a prominent type I interferon signature, with recruitment of plasmacytoid dendritic cells and expression of interferon-inducible chemokines; this is the rationale for interferon-directed and JAK-directed therapeutic programmes.
- CD8+ cytotoxic T cells accumulate at the junction and mediate keratinocyte killing; their spatial position relative to the basal layer is informative and is lost on dissociation.
- CLE is characteristically photosensitive, and ultraviolet exposure drives keratinocyte apoptosis and autoantigen exposure — a mechanism best interrogated in skin explants or fixed tissue.
- Paired lesional and non-lesional biopsies from the same donor provide an internally controlled comparison that separates disease-driven change from inter-individual variation.
Donor Stratification Available
- CLE subtype: acute (ACLE), subacute (SCLE), or chronic/discoid (DLE), including scarring and dyspigmented lesions
- Biopsy site: lesional, perilesional, non-lesional exposed, or sun-protected skin
- Serology: ANA titre and pattern, anti-Ro/SSA, anti-La/SSB, anti-dsDNA where documented
- Presence or absence of concurrent systemic lupus erythematosus
- Disease activity and damage assessment, including CLASI scoring where captured
- Treatment status: topical or intralesional corticosteroid, antimalarial (hydroxychloroquine), systemic immunosuppressant, biologic, or treatment-naive
- Fitzpatrick skin type, smoking status, and photosensitivity history
- Matched healthy controls available
Product Features
- Research Use Only (RUO), fresh or frozen skin punch biopsies
- Samples are frozen (if requested) within 4 hours of collection
- Clinically confirmed cutaneous lupus erythematosus donors
- Collected by licensed clinicians under aseptic conditions
- Lesional and non-lesional sites available from the same donor on request
- Processed and shipped same-day where applicable
- IRB-approved protocols and electronic informed consent
De-identified Donor Data
- Verified diagnosis of cutaneous lupus erythematosus and subtype where documented
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported medication history and lesion site
- Serology and disease activity data available upon request
Applications
- Histopathological grading of interface dermatitis and adnexal involvement
- Direct immunofluorescence for immunoglobulin and complement deposition
- Interferon signature scoring by bulk or spatial transcriptomics
- Multiplex immunohistochemistry and imaging mass cytometry of infiltrating T cells and dendritic cells
- Single-cell and spatial profiling of keratinocyte, fibroblast, and immune compartments
- Target validation for interferon-pathway, JAK, and B cell-directed therapeutics
- Ex vivo skin explant assays, including ultraviolet challenge models
- Biomarker discovery differentiating CLE subtypes and predicting scarring outcomes
Other Cutaneous Lupus Erythematosus Specimen Types
- Cutaneous Lupus Erythematosus Serum
- Cutaneous Lupus Erythematosus Plasma
- Cutaneous Lupus Erythematosus Whole Blood
- Cutaneous Lupus Erythematosus PBMC
- Cutaneous Lupus Erythematosus Leukopak
- Cutaneous Lupus Erythematosus Bulk Plasma
Compliance and Quality Assurance
- IRB-approved collections and SOP-driven processing
- 21 CFR Part 11-compliant electronic informed consent
- HIPAA-compliant donor data management
Ordering & Customization
Cutaneous Lupus Erythematosus Skin Punch Biopsy samples can be shipped ambient, refrigerated, or on dry ice. For pricing, availability, orders outside the United States, or regulatory documentation, please contact learnmore@sanguinebio.com. To browse other disease states and biopsy formats, visit our human skin punch biopsy page.
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Skin Punch Biopsy cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.